Table 3.

Patients treated with TKIs.

SUMMARY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND ASSOCIATED AVNFH
PATIENT	PATIENT (Yrs)	GENDER	INTERVAL FROM CML dx TO DEVELOPMENT OF AVN	PLATELET AND WBC COUNTS AT TIME OF AVN dx	TKI DOSE	OTHER Rx	COMMENT
1	12	Male	8 years	WBC 5600/mm3	Start dose 400 mg/d; escalated to 600 mg/d to achieve complete cytogenetic response		Dx as CML (chronic phase in 2005; started on imatinib 400 mg (340 mg/m2) after 20 months dose escalated to 600 mg/day (continued for 1 yr)16
2	34	Female	3 years	WBC 6000, Hb 13 g/dl, and Plts 235/l	Failed imatinib 400 mg then shifted to Dasatinib 100 mg		Developed AVNFH 18 months after dastinib in CHR, CCR, MMR17